Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 11/20 | 0.62 |
| ▸ | RARG | P13631 | 10/20 | 0.62 |
| ▸ | RARA | P10276 | 8/20 | 0.62 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CYP26B1 | Q9NR63 | 4/20 | 0.59 |
| ▸ | RXRA | P19793 | 9/20 | 0.58 |
| ▸ | RXRB | P28702 | 8/20 | 0.58 |
| ▸ | RXRG | P48443 | 6/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407891 | 0.85 | RARB (0.64) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL10246895 | 0.85 | RARB (0.64) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19072651 | 0.83 | CYP3A4 (0.63) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL2195010 | 0.81 | RXRA (0.63) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8733241 | 0.80 | RARB (0.83) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9189898 | 0.80 | CYP3A4 (0.59) | RARBRARGRARACYP26A1CYP3A4 | |
| Hydrazine SCHEMBL9430381 | 0.79 | RARB (0.76) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL846110 | 0.79 | RARB (0.81) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL29827631 | 0.79 | RARB (0.81) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL2195224 | 0.79 | RXRA (0.66) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| EP-2513066-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
| US-20100056507-A1 | PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2010-03-04 | — | — | US | disclosed |
| EP-2102162-A1 | PHENYLIC DERIVATIVES AND USE THEREOF AS DRUGS | IPSEN PHARMA S.A.S. (FR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008059128-A1 | PHENYLIC DERIVATIVES AND USE THEREOF AS DRUGS | IPSEN PHARMA S.A.S. (FR) | 2008-05-22 | — | — | WO | disclosed |
| US-5475017-A | Skin disorders, antitumor agents; side effect reduction | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| US-5206242-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| US-5196532-A | Treatment of skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-23 | — | — | US | disclosed |
| US-5061705-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1991-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056507-A1 | PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT | CNR2, CNR1, TRPV1 | RARB 1659/4885RARG 1808/4885RARA 1438/4885 |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, S1PR3, SPHK2 | RARB 4278/4885RARG 2466/4885RARA 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.